324 related articles for article (PubMed ID: 14751085)
1. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
Krieg AM
Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
[TBL] [Abstract][Full Text] [Related]
2. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
5. Antiinfective applications of toll-like receptor 9 agonists.
Krieg AM
Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
7. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
8. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
McCluskie MJ; Krieg AM
Curr Top Microbiol Immunol; 2006; 311():155-78. PubMed ID: 17048708
[TBL] [Abstract][Full Text] [Related]
10. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Chaput N; Schartz NE; André F; Taïeb J; Novault S; Bonnaventure P; Aubert N; Bernard J; Lemonnier F; Merad M; Adema G; Adams M; Ferrantini M; Carpentier AF; Escudier B; Tursz T; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2137-46. PubMed ID: 14764679
[TBL] [Abstract][Full Text] [Related]
11. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
12. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
13. A Toll-like receptor recognizes bacterial DNA.
Hemmi H; Takeuchi O; Kawai T; Kaisho T; Sato S; Sanjo H; Matsumoto M; Hoshino K; Wagner H; Takeda K; Akira S
Nature; 2000 Dec; 408(6813):740-5. PubMed ID: 11130078
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells.
Vollmer J; Jurk M; Samulowitz U; Lipford G; Forsbach A; Wüllner M; Tluk S; Hartmann H; Kritzler A; Müller C; Schetter C; Krieg AM
J Endotoxin Res; 2004; 10(6):431-8. PubMed ID: 15588427
[TBL] [Abstract][Full Text] [Related]
16. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
Ahmad-Nejad P; Häcker H; Rutz M; Bauer S; Vabulas RM; Wagner H
Eur J Immunol; 2002 Jul; 32(7):1958-68. PubMed ID: 12115616
[TBL] [Abstract][Full Text] [Related]
17. A Toll for lupus.
Anders HJ
Lupus; 2005; 14(6):417-22. PubMed ID: 16038103
[TBL] [Abstract][Full Text] [Related]
18. Role of Toll-like receptors in costimulating cytotoxic T cell responses.
Schwarz K; Storni T; Manolova V; Didierlaurent A; Sirard JC; Röthlisberger P; Bachmann MF
Eur J Immunol; 2003 Jun; 33(6):1465-70. PubMed ID: 12778463
[TBL] [Abstract][Full Text] [Related]
19. Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity.
Kurt-Jones EA; Sandor F; Ortiz Y; Bowen GN; Counter SL; Wang TC; Finberg RW
J Endotoxin Res; 2004; 10(6):419-24. PubMed ID: 15588425
[TBL] [Abstract][Full Text] [Related]
20. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
